Developing the trehalose biosynthesis pathway as an antifungal drug target.
Publication
, Journal Article
Washington, EJ
Published in: NPJ Antimicrob Resist
April 14, 2025
Invasive fungal infections are responsible for millions of deaths worldwide each year. Therefore, focusing on innovative approaches to developing therapeutics that target fungal pathogens is critical. Here, we discuss targeting the fungal trehalose biosynthesis pathway with antifungal therapeutics, which may lead to the improvement of human health globally, especially as fungal pathogens continue to emerge due to fluctuations in the climate.
Duke Scholars
Published In
NPJ Antimicrob Resist
DOI
EISSN
2731-8745
Publication Date
April 14, 2025
Volume
3
Issue
1
Start / End Page
30
Location
England
Citation
APA
Chicago
ICMJE
MLA
NLM
Washington, E. J. (2025). Developing the trehalose biosynthesis pathway as an antifungal drug target. NPJ Antimicrob Resist, 3(1), 30. https://doi.org/10.1038/s44259-025-00095-2
Washington, Erica J. “Developing the trehalose biosynthesis pathway as an antifungal drug target.” NPJ Antimicrob Resist 3, no. 1 (April 14, 2025): 30. https://doi.org/10.1038/s44259-025-00095-2.
Washington EJ. Developing the trehalose biosynthesis pathway as an antifungal drug target. NPJ Antimicrob Resist. 2025 Apr 14;3(1):30.
Washington, Erica J. “Developing the trehalose biosynthesis pathway as an antifungal drug target.” NPJ Antimicrob Resist, vol. 3, no. 1, Apr. 2025, p. 30. Pubmed, doi:10.1038/s44259-025-00095-2.
Washington EJ. Developing the trehalose biosynthesis pathway as an antifungal drug target. NPJ Antimicrob Resist. 2025 Apr 14;3(1):30.
Published In
NPJ Antimicrob Resist
DOI
EISSN
2731-8745
Publication Date
April 14, 2025
Volume
3
Issue
1
Start / End Page
30
Location
England